Catalent today priced an underwritten public offering for 6,395,000 shares of its common stock at $39.10 apiece. The offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica.
In connection with the offering, Catalent granted underwriters a 30-day option to buy up to an additional 959,250 shares of common stock sold at the public offering price.
Get the full story at our sister site, Drug Delivery Business News.
The post Catalent prices offering to help fund Cook Pharmica acquisition appeared first on MassDevice.